Correlation Between Eupraxia Pharmaceuticals and BRISTOL MYERS

Can any of the company-specific risk be diversified away by investing in both Eupraxia Pharmaceuticals and BRISTOL MYERS at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eupraxia Pharmaceuticals and BRISTOL MYERS into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eupraxia Pharmaceuticals Common and BRISTOL MYERS SQUIBB, you can compare the effects of market volatilities on Eupraxia Pharmaceuticals and BRISTOL MYERS and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eupraxia Pharmaceuticals with a short position of BRISTOL MYERS. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eupraxia Pharmaceuticals and BRISTOL MYERS.

Diversification Opportunities for Eupraxia Pharmaceuticals and BRISTOL MYERS

0.0

Correlation Coefficient

Eupraxia Pharmaceuticals  BRISTOL MYERS

Pay attention - limited upside

The 3 months correlation between Eupraxia and BRISTOL is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Eupraxia Pharmaceuticals Commo and BRISTOL MYERS SQUIBB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BRISTOL MYERS SQUIBB and Eupraxia Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eupraxia Pharmaceuticals Common are associated (or correlated) with BRISTOL MYERS. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BRISTOL MYERS SQUIBB has no effect on the direction of Eupraxia Pharmaceuticals i.e., Eupraxia Pharmaceuticals and BRISTOL MYERS go up and down completely randomly.

Pair Corralation between Eupraxia Pharmaceuticals and BRISTOL MYERS

If you would invest  295.00  in Eupraxia Pharmaceuticals Common on September 27, 2024 and sell it today you would earn a total of  11.00  from holding Eupraxia Pharmaceuticals Common or generate 3.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

Eupraxia Pharmaceuticals Commo  vs.  BRISTOL MYERS SQUIBB

Eupraxia Pharmaceuticals

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

BRISTOL MYERS SQUIBB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days BRISTOL MYERS SQUIBB has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable essential indicators, BRISTOL MYERS is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Eupraxia Pharmaceuticals and BRISTOL MYERS

The main advantage of trading using opposite Eupraxia Pharmaceuticals and BRISTOL MYERS positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eupraxia Pharmaceuticals position performs unexpectedly, BRISTOL MYERS can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BRISTOL MYERS will offset losses from the drop in BRISTOL MYERS's long position.

The idea behind Eupraxia Pharmaceuticals Common and BRISTOL MYERS SQUIBB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.